Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company focused on the life sciences and healthcare sector, targeting businesses at the intersection of scientific innovation and commercial development. The company filed a Form 10-Q with the SEC on November 14, 2025, under accession number 0001104659-25-112494, reflecting its continued reporting obligations as a public entity. TDAC completed its initial public offering in 2021, during the peak of the SPAC market, and has pursued acquisition targets within the biotechnology and translational medicine space. Investors and analysts tracking the company's deal timeline, shareholder composition, and filing history can access the full data profile on SpacDesk — sign up at spacdesk.com for comprehensive SPAC coverage.